What results do women see in the first month on Wegovy?

Why is weight loss usually modest in the very first weeks?

The 0.25mg starting dose serves one purpose: giving your gut time to adapt to semaglutide before the therapeutic doses begin. At that level, appetite suppression is real but mild. Gastric emptying slows, and many women notice food feels more filling than usual, but the hormonal signalling that drives meaningful weight loss strengthens as the dose climbs. Most prescribers titrate to 0.5mg at week five, then 1mg, 1.7mg and eventually 2.4mg, each step roughly four weeks apart.

Because of that staircase, a first-month loss of one to three kilograms is clinically normal and a good sign, not a disappointment. Your body is tolerating the medicine and laying the groundwork. The changes that appear in the first week (reduced hunger, smaller portions feeling satisfying) are the early signals that the medicine is working, even if the scales are slow to reflect it.

Weight loss in women can also be shaped by menstrual-cycle water retention, which can mask fat loss on the scale for a week or two at a time. Tracking measurements alongside weight gives a fuller picture in these early weeks, and before-and-after comparisons from the first month of Wegovy can help set realistic expectations for what that progress actually looks like.

What does the clinical trial evidence actually show over the longer arc?

The landmark STEP 1 trial, published in the New England Journal of Medicine, randomised 1,961 adults with obesity and found an average body-weight reduction of around 15% over 68 weeks at the 2.4mg maintenance dose. The majority of participants were women. That 15% figure is an average: some participants lost more, some less, and the rate of loss tended to accelerate through months two to six as doses increased.

It is worth being clear that this evidence comes from a controlled trial with lifestyle support alongside the medicine. Real-world results vary. The NHS semaglutide medicines page notes that Wegovy works best when combined with a reduced-calorie diet and increased physical activity, not because willpower drives the outcome, but because the medicine and lifestyle changes work through overlapping biological pathways.

For women curious about what results look like at the one-month mark specifically, including what a typical trajectory looks like across dose steps, the one-month Wegovy results page covers the data in more detail.

Does being female affect how Wegovy works or what to expect?

Biological sex can influence the pace and pattern of weight loss on GLP-1 medicines, though both men and women respond. Women in trials sometimes experience a slightly slower initial rate of loss, partly because oestrogen affects body-composition targets and partly because menstrual-cycle fluctuations can obscure fat loss on the scale.

There is also a contraception consideration specific to GLP-1 treatment. NHS England advises that women on oral contraceptive pills consider additional contraceptive cover, particularly when starting or changing doses, because slowed gastric emptying may affect oral-pill absorption. This is a conversation to have with a prescriber at the consultation stage, not something to navigate alone.

For women approaching or past the menopause, results are still achievable, but the interplay between GLP-1 treatment and HRT is worth discussing: NHS guidance suggests that transdermal forms of HRT (patches or gels) are preferable to oral HRT while on these medicines for the same absorption-related reason. The clinical team at our pharmacy reviews these individual circumstances as part of the assessment process.

Wegovy is a prescription-only medicine, and the private-route context for women who want to begin without a long NHS wait is covered on the Wegovy overview page. If cost is a factor in your thinking, the Wegovy pricing page explains what a legitimate private prescription includes.

When should a woman be concerned about her first-month progress?

Slow initial weight loss is not a signal to stop. If the first month brings mainly side effects and minimal change on the scale, that is common, and manageable. Nausea, loose stools, or constipation are the most frequently reported early experiences. They typically settle within a week or two of each dose step, and what to expect during the first month on Wegovy covers how to reduce discomfort during the early weeks.

There are situations that do need prompt medical attention: severe or persistent stomach pain that spreads to the back (which can be a sign of pancreatitis), signs of a serious allergic reaction, or symptoms of dehydration following prolonged vomiting or diarrhoea. If any of those occur, contact a healthcare professional the same day rather than waiting for a routine check-in. Side effects can also be reported at the MHRA's Yellow Card scheme, which helps regulators monitor medicines in real-world use.

If you are on Wegovy and your progress at six months is under 5% body weight, NICE guidance suggests that continuing the medicine should be reviewed with your prescriber. That threshold is a clinical check, not a verdict, it exists to make sure the medicine is genuinely helping you.

If you would like a prescriber to review whether Wegovy is the right starting point for your situation, check your eligibility with our clinical team.